Category Archives: Biochemistry

Phage therapy: A new old… – ScienceBlog.com

The fight against drug-resistant pathogens remains an intense one. While the Centers for Disease Controls (CDC) 2019 biggest threats report reveals an overall decrease in drug-resistant microbe-related deaths as compared to its previous report (2013) the agency also cautions that new forms of drug-resistant pathogens are still emerging.

Meanwhile, the options for treating infections by these germs are diminishing, confirming doctors and scientists worries about the end of the age of antibiotics.

We knew it was going to be a problem early on, said UC Santa Barbara chemistry and biochemistry professorIrene Chen. Basically as soon as penicillin was discovered, a few years later it was reported that there was a resistant organism. Thanks to factors such as horizontal gene transfer and rapid reproduction, organisms such as Gram-negative bacteria are able to evolve faster than we can produce antibiotics to control them.

So Chen and her research group are seeking alternatives to antibiotics, in a growing effort to head off the tide of incurable bacterial infections. In their work, the group has turned to bacteriophages, a naturally occurring group of viruses that colonize on bacteria.

Thats their natural function, really, to grow on and kill bacteria, said Chen, author of apaperthat appears in the Proceedings of the National Academy of Sciences. By taking advantage of the bacteriophages ability to home in on specific bacteria without damaging the rest of the microbiome, the researchers were able to use a combination of gold nanorods and near-infrared light to destroy even multidrug-resistant bacteria without antibiotics.

Phage therapy isnt new, Chen said. In fact, it has been used in the former Soviet Union and Europe for about a century, though they are seen largely as last-resort alternatives to antibiotics. Among the unresolved issues of phage therapy is the incomplete characterization of the phages biology a biology that could allow for unintended consequences due to the phages own rapid evolution and reproduction, as well as potential toxins the viruses may carry. Another issue is the all-or-nothing aspect of phage therapy, Chen added.

Its difficult to analyze the effect of a phage treatment, she said. You might see it completely work or you might see it completely fail, but you dont have the kind of dose response you want.

To surmount these challenges, the Chen lab developed a method of controlled phage therapy.

What we did was to conjugate the phages to gold nanorods, she explained. These phanorods were applied to bacteria on in-vitro cultures of mammalian cells and then exposed to near-infrared light.

Conjugated to phages,gold nanorods find their target: a bacterial cell wall

Photo Credit:COURTESY IMAGE

When these nanorods are photo-excited, they translate the energy from light to heat, Chen said, and that creates very high local temperatures.

The heat is enough to kill the bacteria, and it also kills the phages, preventing any unwanted further evolutions. The result is a guided missile of targeted phage therapy that also allows for dosage control. The lab found success in destroyingE. coli,P. aeruginosaandV. cholerae human pathogens that cause acute symptoms if left unchecked. They also were able to successfully destroyX. campestris, a bacteria that causes rot in plants.

In a collaboration with UC Santa Barbara mechanical engineerBeth Pruitt, the lab determined that while the heat successfully destroyed bacteria and phage, more than 80% of the mammalian cell culture underneath the bacteria biofilm survived.

Bacteria under fire: Green bacteria are alive, while the red ones are dead

Photo Credit:COURTESY IMAGE

This issue of whether it damages mammalian tissues is very important, Chen said. Work in nanotechnology and nanomedicine treating bacterial infections indicates that when its non-targeted, it really does burden the surrounding tissues.

The lab plans to investigate other possible phages to counter other bacteria, possibly engineering a photothermal method that could treat multiple bacterial infections.

Research on this study was conducted also by UCSB postdoctoral fellow Huan Peng (lead author), Raymond E. Borg and Liam P. Dow.

Read more:
Phage therapy: A new old... - ScienceBlog.com

Dr. Lisak honored with Healthcare Professional Champion Award for efforts against MS – The South End

Wayne State University School of Medicine Professor of Neurology Robert Lisak, M.D., FRCP, FAAN, received the Healthcare Professional Champion Award from the Michigan Chapter of the National Multiple Sclerosis Society.

The award is presented to an individual who has demonstrated their commitment to helping people meet the challenges of Multiple Sclerosis, including improving access to and quality of MS clinical care. Recipients must have demonstrated leadership in establishing relationships with other health care providers and professional organizations, increasing referrals to the society and improving MS knowledge in the health care workforce.

It is nice to be recognized for doing things that you enjoy doing for others, said Dr. Lisak, who received the honor Jan. 11 at the chapters annual Breakthroughs in MS meeting in Novi. Mich.

Mirela Cerghet, M.D., Ph.D., a neurologist with the Henry Ford Health System, presented Dr. Lisak, also a professor of Biochemistry, Microbiology and Immunology, and former chair of WSU Neurology, with the award on behalf of the chapter.

Dr. Lisak, said Dr. Cerghet, has been a champion for patients living with MS for the entire span of his distinguished career. His involvement with the National MS Society spans decades, and over the years of his service great strides have been made toward creating a world free of MS, including the development of all the disease-modifying medications.

A member of the societys Board of Trustees and chair of the Healthcare Provider Council, Dr. Lisak has played a critical role in attracting new talent to the field through his involvement in MS professional education, medical student mentoring, clinical training programs and engagement with clinical fellows, Dr. Cerghet said.

Most recently, Dr. Lisak, representing both WSU and the Consortium of Multiple Sclerosis Centers in his role on the AAN Guideline Development, Dissemination and Implementation Subcommittee, helped develop new guidelines for disease-modifying therapy for multiple sclerosis. The Consortium of Multiple Sclerosis Centers is a professional organization of MS centers and health care providers and researchers in the United States and Canada committed to a comprehensive multidisciplinary approach to treatment and care, education and research and advocacy for MS so that the centers can provide the best care and outcomes for patients and their families. The consortium also is an international clearinghouse for research results, the latest treatments, clinical trials and patient education programs.

Continued here:
Dr. Lisak honored with Healthcare Professional Champion Award for efforts against MS - The South End

January: smoking cessation | News – University of Bristol

As smokers know all too well, nicotine is highly addictive. Its hard to quit smoking, a habit that claims the lives of more than seven million people each year.

Smoking tobacco delivers nicotine to the neuroreceptors responsible for addiction, affecting the nervous system and causing addiction.

A new study, led by scientists from the University of Bristol, into the molecular interactions involved has revealed how these neuroreceptors respond to nicotine.

The researchers used new computational simulation methods to discover how receptors in the brain respond to nicotine.

One of the key features of the study is the speed at which the discovery was made, thanks to the use of Oracle Cloud Infrastructure, which allowed the researchers to run a large number of simulations in unprecedentedly short time.

The work brought together computational chemists, biochemists and research software engineers, working together to deploy large numbers of simulations of nicotine receptors in the cloud.

Reducing the time to results to just five days using Oracles high-performance cloud infrastructure is transformational from a research perspective. Calculations that might otherwise have taken months to complete were completed in a matter of days.

The study, carried out by researchers from Bristol in partnership with Oracle, whose cloud technologies were a key part of the investigation, is reported in the Journal of the American Chemical Society, the flagship publication of the American Chemical Society, the worlds largest scientific society and a global leader in providing access to chemistry-related research. The project was supported by funding from EPSRC.

Co-author of the study, Professor Adrian Mulholland, from Bristols Centre for Computational Chemistry, part of Bristols School of Chemistry, said: Nicotine is highly addictive: its very hard to give up smoking. To understand why it is so addictive, and to make molecules to help people quit, we need to understand how it affects the nervous system.

We have used simulations to model and understand how nicotine affects receptors in the brain. Using the power of cloud computing, we were able to show how nicotine exerts its effects, at the molecular level, the first stage of signaling in the brain. This information, and the methods we have developing, will help in developing new smoking cessation aids.

Researchers are now working with Achieve Life Sciences to design and develop molecules that mimic nicotine, and computer simulations that will help test their potential effectiveness. This work builds on previous studies using chemical synthetic approaches to develop new smoking cessation aids, which will be investigated and tested in simulation scenarios.

Smoking is the second most common cause of death worldwide, but most current anti-smoking drugs are only moderately effective in reducing symptoms of withdrawal and may cause undesirable side effects. New, specific and effective smoking cessation aids are needed.

Nicotine is the major psychoactive agent in tobacco and causes addiction by binding to specific receptors in the brain. Understanding how nicotine binds to these receptors and creates the nicotine hit and subsequent craving is a key focus for public health research.

The study saw researchers perform 450 individual molecular dynamics simulations of the biochemistry associated with the binding of nicotine to a subtype (7) of nicotinic acetylcholine receptors in the brain. They were able to compare with other types nicotine receptor and identify common features of receptor activation.

The study also showed how cloud computing can be combined effectively with more traditional high-performance computing.

This work shows how rigorous simulations can be used to predict effects on drug targets in a matter of days.

On this quick timescale, calculations help to plan and interpret experiments, and will help design and develop effective drugs. More broadly, the agility and other benefits of using cloud computing for research offers the potential to accelerate the pace of discovery dramatically.

Paper:

A general mechanism for signal propagation in the nicotinic acetylcholine receptor family by A. Oliveria, C. Edsall, C. Woods, P. Bates, G. Viedma-Nunez, S. Wonnacott, I. Bermudez, G. Ciccotti, T. Gallagher, R. Sessions and A. Mulholland in Journal of the American Chemical Society

Read this article:
January: smoking cessation | News - University of Bristol

An Astrobiologist Seeks to Explain Whether There Are Other ‘Beings’ Amongst Us – Qrius

Samantha Rolfe, University of Hertfordshire

Life is pretty easy to recognise. It moves, it grows, it eats, it excretes, it reproduces. Simple. In biology, researchers often use the acronym MRSGREN to describe it. It stands for movement, respiration, sensitivity, growth, reproduction, excretion and nutrition.

But Helen Sharman, Britains first astronaut and a chemist at Imperial College London, recently said that alien lifeforms that are impossible to spot may be living among us. How could that be possible?

While life may be easy to recognise, its actually notoriously difficult to define and has had scientists and philosophers in debate for centuries if not millennia. For example, a 3D printer can reproduce itself, but we wouldnt call it alive. On the other hand, a mule is famously sterile, but we would never say it doesnt live.

As nobody can agree, there are more than 100 definitions of what life is. An alternative (but imperfect) approach is describing life as a self-sustaining chemical system capable of Darwinian evolution, which works for many cases we want to describe.

The lack of definition is a huge problem when it comes to searching for life in space. Not being able to define life other than well know it when we see it means we are truly limiting ourselves to geocentric, possibly even anthropocentric, ideas of what life looks like. When we think about aliens, we often picture a humanoid creature. But the intelligent life we are searching for doesnt have to be humanoid.

Sharman says she believes aliens exist and theres no two ways about it. Furthermore, she wonders: Will they be like you and me, made up of carbon and nitrogen? Maybe not. Its possible theyre here right now and we simply cant see them.

Such life would exist in a shadow biosphere. By that, I dont mean a ghost realm, but undiscovered creatures probably with a different biochemistry. This means we cant study or even notice them because they are outside of our comprehension. Assuming it exists, such a shadow biosphere would probably be microscopic.

So why havent we found it? We have limited ways of studying the microscopic world as only a small percentage of microbes can be cultured in a lab. This may mean that there could indeed be many lifeforms we havent yet spotted. We do now have the ability to sequence the DNA of unculturable strains of microbes, but this can only detect life as we know it that contain DNA.

If we find such a biosphere, however, it is unclear whether we should call it alien. That depends on whether we mean of extraterrestrial origin or simply unfamiliar.

A popular suggestion for an alternative biochemistry is one based on silicon rather than carbon. It makes sense, even from a geocentric point of view. Around 90% of the Earth is made up of silicon, iron, magnesium and oxygen, which means theres lots to go around for building potential life.

Silicon is similar to carbon, it has four electrons available for creating bonds with other atoms. But silicon is heavier, with 14 protons (protons make up the atomic nucleus with neutrons) compared to the six in the carbon nucleus. While carbon can create strong double and triple bonds to form long chains useful for many functions, such as building cell walls, it is much harder for silicon. It struggles to create strong bonds, so long-chain molecules are much less stable.

Whats more, common silicon compounds, such as silicon dioxide (or silica), are generally solid at terrestrial temperatures and insoluble in water. Compare this to highly soluble carbon dioxide, for example, and we see that carbon is more flexible and provides many more molecular possibilities.

Life on Earth is fundamentally different from the bulk composition of the Earth. Another argument against a silicon-based shadow biosphere is that too much silicon is locked up in rocks. In fact, the chemical composition of life on Earth has an approximate correlation with the chemical composition of the sun, with 98% of atoms in biology consisting of hydrogen, oxygen and carbon. So if there were viable silicon lifeforms here, they may have evolved elsewhere.

That said, there are arguments in favour of silicon-based life on Earth. Nature is adaptable. A few years ago, scientists at Caltech managed to breed a bacterial protein that created bonds with silicon essentially bringing silicon to life. So even though silicon is inflexible compared with carbon, it could perhaps find ways to assemble into living organisms, potentially including carbon.

And when it comes to other places in space, such as Saturns moon Titan or planets orbiting other stars, we certainly cant rule out the possibility of silicon-based life.

To find it, we have to somehow think outside of the terrestrial biology box and figure out ways of recognising lifeforms that are fundamentally different from the carbon-based form. There are plenty of experiments testing out these alternative biochemistries, such as the one from Caltech.

Regardless of the belief held by many that life exists elsewhere in the universe, we have no evidence for that. So it is important to consider all life as precious, no matter its size, quantity or location. The Earth supports the only known life in the universe. So no matter what form life elsewhere in the solar system or universe may take, we have to make sure we protect it from harmful contamination whether it is terrestrial life or alien lifeforms.

So could aliens be among us? I dont believe that we have been visited by a life form with the technology to travel across the vast distances of space. But we do have evidence for life-forming, carbon-based molecules having arrived on Earth on meteorites, so the evidence certainly doesnt rule out the same possibility for more unfamiliar life forms.

Samantha Rolfe, Lecturer in Astrobiology and Principal Technical Officer at Bayfordbury Observatory, University of Hertfordshire

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Stay updated with all the insights.Navigate news, 1 email day.Subscribe to Qrius

Originally posted here:
An Astrobiologist Seeks to Explain Whether There Are Other 'Beings' Amongst Us - Qrius

Postdoctoral Fellowship Under A Indo-French Academia-Industry job with VELLORE INSTITUTE OF TECHNOLOGY | 192385 – Times Higher Education (THE)

Job Description

Applications are invited for a temporary Post ofPostdoctoral Fellowship under a Indo-French Academia-Industry Collaborative Projectfunded by CEFIPRA, in Centre for Bio Separation Technology, Vellore Institute of Technology (VIT).

Title of the Project:

Cost effective strategy for the induction of immune tolerance to therapeutic Factor VIII in haemophilia A

Qualification:

PhD in Biochemistry /Molecular Biology/Genetic Engineering/Biotechnology/ Microbiology/Life Sciences

Desirable (if any):

Experience in molecular cloning, expression and purification of proteins

Stipend:Rs.47,000/ per month + 10% HRASponsoring Agency:CEFIPRADuration:Upto April 2020 (3 months)

Principal Investigator:

Principal Investigator: Dr.Krishnan V (Professor & Director, Centre for BioSeparation Technology)

Coinvestigator: Prof.M.A.Vijyalakshmi (Professor, Centre for BioSeparation Technology)

Send your resume along with relevant documents pertaining to the details of qualifications, scientific accomplishments, experience (if any) and latest passport size photo etc. on or before(20/01/2020)through onlinehttp://careers.vit.ac.in

Salary:Not Disclosed by RecruiterIndustry:Education / Teaching / TrainingFunctional Area:Teaching, Education, Training, CounsellingRole:Trainee

Keyskills

immune toleranceBiochemistry/

Desired Candidate Profile

Please refer to the Job description above

Education-

Doctorate:Ph.D - Microbiology, Bio-Chemistry/Bio-Technology

Company Profile

Vellore Institute of Technology

VIT was established with the aim of providing quality higher education on par with international standards. It persistently seeks and adopts innovative methods to improve the quality of higher education on a consistent basis.The campus has a cosmopolitan atmosphere with students from all corners of the globe. Experienced and learned teachers are strongly encouraged to nurture the students. The global standards set at VIT in the field of teaching and research spur us on in our relentless pursuit of excellence. In fact, it has become a way of life for us. The highly motivated youngsters on the campus are a constant source of pride. Our Memoranda of Understanding with various international universities are our major strength. They provide for an exchange of students and faculty and encourage joint research projects for the mutual benefit of these universities. Many of our students, who pursue their research projects in foreign universities, bring high quality to their work and esteem to India and have done us proud. With steady steps, we continue our march forward. We look forward to meeting you here at VIT.

Excerpt from:
Postdoctoral Fellowship Under A Indo-French Academia-Industry job with VELLORE INSTITUTE OF TECHNOLOGY | 192385 - Times Higher Education (THE)

Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug…

SEATTLE and VANCOUVER, British Columbia, Jan. 13, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (Nasdaq: ACHV), University of Bristol, and Oracle Corporation (NYSE: ORCL) today announced the outcome of a study using Oracle's high-performance cloud infrastructure to potentially improve the speed of drug discovery and development of new treatments.

The study, "A General Mechanism for Signal Propagation in the Nicotinic Acetylcholine Receptor Family," wasled by scientists from the University of Bristol and recently published in the Journal of the American Chemical Society. It aimed to evaluate how receptors in the brain respond to nicotine. Researchers utilized new computational simulation methods to conduct 450 individual assessments of the biochemistry associated with the binding of nicotine to a subtype of nicotinic acetylcholine receptors, a key mechanism believed to be responsible for the highly-addictive nature of nicotine.

Computations that would otherwise have taken months to complete were achieved in five days using Oracle's high-performance cloud infrastructure. The speed of results represents a breakthrough in computational chemistry and is transformational from a research perspective.

"To understand why nicotine is so addictive, and to develop molecules to help people quit smoking, we need to understand how nicotine affects the nervous system," commented Professor Adrian Mulholland from Bristol's Centre for Computational Chemistry and co-author of the study. "By harnessing the power of cloud computing, we can quickly observe how nicotine exerts its effects at the molecular level. This information can inform future drug development of new treatments for companies like Achieve."

Achieve Life Sciences has partnered with the University of Bristol to formulate molecules and potential treatments to combat addiction and neurological disorders based on their lead smoking cessation compound in development, cytisinicline. Building on this research and previously conducted studies, cloud-based computer simulations can now be utilized to evaluate the effectiveness of potential new treatments more efficiently and help to accelerate the pace of discovery.

About Achieve & Cytisinicline Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths annually worldwide.1 It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking.2 Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities, the potential market size for cytisinicline, the potential benefits of cytisinicline, the ability to discover and develop new uses for cytisinicline and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve ContactJason Wongjwong@bplifescience.com(415) 375-3340 ext. 4

1World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017 2Annals of Epidemiology, Volume 25, Issue 3, 179 - 182.e1

View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-university-of-bristol-and-oracle-corporation-announce-study-results-demonstrating-potential-for-accelerated-speed-of-drug-discovery-300985427.html

SOURCE Achieve Life Sciences, Inc.

Continue reading here:
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug...

Alien bombshell: Why ‘it’s possible’ ‘invisible’ aliens are hiding somewhere on Earth – Express.co.uk

Britains first astronaut Helen Sharman recently hit the headlines after announcing impossible-to-spot aliens may already be living among us. Life as we understand it is easy to recognise: living things move, grow, eat, excrete and reproduce.

However, while life might be easy to spot, it is actually notoriously difficult to define and has had scientists and philosophers in debate for millennia.

The intelligent life we are searching for doesnt have to be humanoid

Dr Samantha Rolfe

There are more than 100 definitions of what life is.

An alternative but imperfect approach is describing life as a self-sustaining chemical system capable of Darwinian evolution, which works for many cases we want to describe.

Dr Samantha Rolfe, the astrobiology and principal technical officer at Bayfordbury Observatory, believes it is this lack of definition that presents problems when searching for life in space.

READ MORE:NASA unveils stunning photo of ISS transiting Sun

She wrote in The Conversation: Not being able to define life other than well know it when we see it means we are truly limiting ourselves to geocentric, possibly even anthropocentric, ideas of what life looks like.

When we think about aliens, we often picture a humanoid creature.

But the intelligent life we are searching for doesnt have to be humanoid.

Ms Sharman recently courted controversy after announcing aliens exist and theres no two ways about it.

DON'T MISSTESS satellite presents stunning new southern sky mosaic[VIDEO]Life discovered deep underground points to subterranean Galapagos'[INTERVIEW]Shadow land: Alien life can exist in 2D universe'[INTERVIEW]

The pioneering space explorer said: Will they be like you and me, made up of carbon and nitrogen?

Maybe not. Its possible theyre here right now and we simply cant see them.

Dr Rolf added: Such life would exist in a shadow biosphere, meaning this alien life would exhibit different biochemistry.

This alien life would consequently be outside of the realm of comprehension for humans.

Assuming it exists, such a shadow biosphere would probably be microscopic.

The Bayfordbury Observatory expert believes this alien life has not already been found due to the limited ways of studying the microscopic world.

She said: This may mean that there could indeed be many lifeforms we havent yet spotted.

We do now have the ability to sequence the DNA of unculturable strains of microbes, but this can only detect life as we know it that contain DNA.

If we find such a biosphere, however, it is unclear whether we should call it alien.

That depends on whether we mean of extraterrestrial origin or simply unfamiliar.

One popular suggestion for alternative biochemistry is one based on silicon rather than carbon.

Proponents for this position argue approximately 90 percent of the Earth is made up of silicon, iron, magnesium and oxygen, meaning there is plenty of material for building potential life.

Silicon is similar to carbon, it has four electrons available for creating bonds with other atoms.

Silicon is, however, heavier, with 14 protons compared to the six in the carbon nucleus.

While carbon can create strong double and triple bonds to form long chains useful for many functions, such as building cell walls, it is much harder for silicon.

Silicon struggles to create strong bonds, meaning long-chain molecules are far less stable.

In addition, common silicon compounds, such as silicon dioxide are generally solid at terrestrial temperatures and insoluble in water.

When compared to soluble carbon dioxide, carbon is more flexible and provides many more molecular possibilities.

Life on Earth is fundamentally different from the bulk composition of the Earth.

Another argument against a silicon-based shadow biosphere is that too much silicon is locked up in rocks.

The chemical composition of life on Earth has an approximate correlation with the chemical composition of the sun, with 98 percent of atoms in biology consisting of hydrogen, oxygen and carbon.

Therefore, if there were viable silicon lifeforms on this planet, they may have evolved elsewhere.

However, silicon-based life cannot be ruled-out, the researcher revealed.

Dr Rolfeuch wrote: Only a few years ago, scientists at Caltech managed to breed a bacterial protein that created bonds with silicon essentially bringing silicon to life.

So even though silicon is inflexible compared with carbon, it could perhaps find ways to assemble into living organisms, potentially including carbon.

And when it comes to other places in space, such as Saturns moon Titan or planets orbiting other stars, we certainly cant rule out the possibility of silicon-based life.

Go here to read the rest:
Alien bombshell: Why 'it's possible' 'invisible' aliens are hiding somewhere on Earth - Express.co.uk

Biochemistry Analysers Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2030 – Citi Blog News

In 2018, the market size of Biochemistry Analysers Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Biochemistry Analysers .

This report studies the global market size of Biochemistry Analysers , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2518517&source=atm

This study presents the Biochemistry Analysers Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Biochemistry Analysers history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Biochemistry Analysers market, the following companies are covered:

Thermo Fisher ScientificAbbottHORIBASiemens HealthcareXylem AnalyticsAgappe DiagnosticsRMSMicroLab InstrumentsLabindia Instruments

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeFully Automated Biochemistry AnalyserSemi Automated Biochemistry Analyser

Segment by ApplicationHospital and Diagnostic LaboratoriesHome CareAcademic and Research Institutes

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2518517&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Biochemistry Analysers product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Biochemistry Analysers , with price, sales, revenue and global market share of Biochemistry Analysers in 2017 and 2018.

Chapter 3, the Biochemistry Analysers competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Biochemistry Analysers breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2518517&licType=S&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Biochemistry Analysers market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Biochemistry Analysers sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Original post:
Biochemistry Analysers Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2030 - Citi Blog News

Liz Bonnin: I was nearly devoured by my tiger project in Nepal – The Times

Wildlife TV presenter LizBonnin recalls doing a masters in wild animal biology and feeling like shed bitten off way more than she could chew when trying to plan an overseas trip to study the eating habits of big cats in a national park near Kathmandu

Interview by Larissa Nolan

I studied biochemistry at Trinity College Dublin. I have always been passionate about science. It is my first love and it always will be understanding how living things work, down to the chemical equations that explain them.

I had done a project on degenerative diseases and applied for a PhD as the next logical step, and I was accepted at Oxford. But I wanted to work more on learning about how to protect the planet and wildlife, which is how I ended up doing a masters in wild animal biology in the Royal Veterinary College and Zoological Society of London instead.

I wrote to them. At first they said, Well consider your application and I said, No, no can I please come in and

Want to read more?

Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.

Investors may be on a high, but US equities are set for a low

This week whynot

More here:
Liz Bonnin: I was nearly devoured by my tiger project in Nepal - The Times

Antibiotics could be promising therapy for certain forms of dementia – Specialty Medical Dialogues

................................ Advertisement ................................

USA: Frontotemporal dementia is the most common type of early-onset dementia. It typically begins between ages 40 and 65 and affects the frontal and temporal lobes of the brain, which leads to behavior changes, difficulty speaking and writing, and memory deterioration. Now, a recent study published in the journal Human Molecular Genetics has found a class of antibiotics called aminoglycosides to be a promising treatment for frontotemporal dementia.

These results could be promising for drug development. Currently, there are no effective therapies for any type of dementia.

A subgroup of patients with frontotemporal dementia has a specific genetic mutation that prevents brain cells from making a protein called progranulin. Although progranulin is not widely understood, its absence is linked to the disease.

................................ Advertisement ................................

These patients brain cells have a mutation that prevents progranulin from being made. The researchers found that by adding a small antibiotic molecule to the cells, they could trick the cellular machinery into making it, said Matthew Gentry, a co-author of the study and the Antonio S. Turco Endowed Professor in the Department of Molecular and Cellular Biochemistry.

................................ Advertisement ................................

Haining Zhu, Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, and colleagues discovered that after the addition of aminoglycoside antibiotics to neuronal cells with this mutation, the cells started making the full-length progranulin protein by skipping the mutation.

The researchers found two specific aminoglycoside antibiotics Gentamicin and G418 were both effective in fixing the mutation and making the functional progranulin protein. After adding Gentamicin or G418 molecules to the affected cells, the progranulin protein level was recovered up to about 50 to 60%.

After this preclinical proof of concept study, the next step is to study the antibiotics effects on mice with the mutation that causes frontotemporal dementia, Zhu says. Another focus is to possibly develop new compounds from Gentamicin and G418 that could be safer and more effective. Although Gentamicin is an FDA-approved medication, its clinical usage is limited as it is associated with a number of adverse side effects.

If we can get the right resources and physician to work with, we could potentially repurpose this drug. This is an early stage of the study, but it provides an important proof of concept that these aminoglycoside antibiotics or their derivatives can be a therapeutic avenue for frontotemporal dementia, said Zhu.

................................ Advertisement ................................

The study, Frontotemporal dementia nonsense mutation of progranulin rescued by aminoglycosides, is published in the journal Human Molecular Genetics.

DOI: https://doi.org/10.1093/hmg/ddz280

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. 2020 Minerva Medical Treatment Pvt Ltd

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted atmedha@medicaldialogues.in. Contact no. 011-43720751

To know about our editorial teamclick here

Source: With inputs from Human Molecular Genetics

................................ Advertisement ................................

Read this article:
Antibiotics could be promising therapy for certain forms of dementia - Specialty Medical Dialogues